Sugi Predict

Sugi Predict / Compounds / SCHEMBL1684402

SCHEMBL1684402

SCHEMBL1684402

CC(C)(C)c1ccc(N)cc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.39
▸ GAA P10253 2/20 0.39
▸ ALDH1A1 P00352 6/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NR1H4 Q96RI1 2/20 0.36
▸ TSHR P16473 3/20 0.35
▸ GLA P06280 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ ALOX15 P16050 3/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ CASP1 P29466 3/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ CYP3A4 P08684 3/20 0.32
▸ PDE10A Q9Y233 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30901480 1.00 MAPT (0.39) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL3546926 0.82 TSHR (0.40) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL14457524 0.79 MAPT (0.33) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL30987853 0.78 TSHR (0.44) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL2379371 0.78 TSHR (0.44) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL2816595 0.78 ALDH1A1 (0.33) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL1039295 0.77 GAA (0.56) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL12732927 0.76 ALOX15 (0.42) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL398357 0.76 CASP1 (0.48) MAPTGAAALDH1A1KDM4EMEN1
SCHEMBL4544654 0.74 ALDH1A1 (0.39) MAPTALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062425-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2026-03-05 — — US disclosed
US-12338256-B2 Aza-tetracyclic oxazepine compounds and uses thereof GENENTECH, INC. (US) 2025-06-24 — — US disclosed
US-20250197353-A1 METHOD OF FORMING BOND BY COUPLING REACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-19 — — US disclosed
EP-4526309-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF Genentech, Inc. (US) 2025-03-26 — — EP disclosed
US-20240368186-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2024-11-07 — — US disclosed
EP-4410775-A1 METHOD FOR FORMING BOND THROUGH COUPLING REACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-08-07 — — EP disclosed
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. 2024-01-25 — — US disclosed
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. 2024-01-25 — — US disclosed
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. 2024-01-25 — — US disclosed
WO-2023225302-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2023-11-23 — — WO disclosed
WO-2005070407-A1 METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2005-08-04 — — WO disclosed
US-6911440-B2 Phthalazine derivatives for treating inflammatory diseases NOVARTIS AG (CH) 2005-06-28 — — US disclosed
US-20040142934-A1 Phthalazine derivatives for treating inflammatory diseases BOLD GUIDO (CH) 2004-07-22 — — US disclosed
CN-1507444-A 2,3-diazanaphthalene derivatives with angiogenesis inhibiting activity ��˹��ŵ�� 2004-06-23 — — CN disclosed
US-6706731-B2 WITH ISOQUINOLINE DERIVATIVES AS ANTITUMOR AGENTS NOVARTIS AG (CH) 2004-03-16 — — US disclosed
EP-1387836-A1 PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY Novartis AG (CH) 2004-02-11 — — EP disclosed
US-6686347-B2 RHEUMATIC DISEASES; ANALGESICS; ENZYME INHIBITORS NOVARTIS AG (CH) 2004-02-03 — — US disclosed
WO-2002090346-A1 PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY NOVARTIS AG (CH) 2002-11-14 — — WO disclosed
EP-1254138-A1 PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE Novartis AG (CH) 2002-11-06 — — EP disclosed
WO-2001058899-A1 PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE NOVARTIS AG (CH) 2001-08-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12338256-B2 Aza-tetracyclic oxazepine compounds and uses thereof AZI2, TET3, OXA1L MAPT 3374/4885GAA 2419/4885ALDH1A1 1000/4885
US-20040142934-A1 Phthalazine derivatives for treating inflammatory diseases KDR, FLT1, TIE1 MAPT 632/4885GAA 2126/4885ALDH1A1 843/4885
US-20240025919-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF AZI2, TET3, OXA1L MAPT 3374/4885GAA 2419/4885ALDH1A1 1000/4885
US-20260062425-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF KRAS, NRAS, HRAS MAPT 4847/4885GAA 4548/4885ALDH1A1 908/4885
US-20240368186-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF AZI2, TET3, OXA1L MAPT 3374/4885GAA 2419/4885ALDH1A1 1000/4885
US-20250197353-A1 METHOD OF FORMING BOND BY COUPLING REACTION CBR1, CBR3, NOX4 MAPT 4530/4885GAA 4483/4885ALDH1A1 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.